Regeneron Pharmaceuticals Stock Performance
| REGN Stock | USD 754.87 1.84 0.24% |
The company holds a Beta of 0.82, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Regeneron Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Regeneron Pharmaceuticals is expected to be smaller as well. At this point, Regeneron Pharmaceuticals has a negative expected return of -0.68%. Please make sure to check Regeneron Pharmaceuticals' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Regeneron Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Regeneron Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.24 | Five Day Return 1.37 | Year To Date Return (16.59) | Ten Year Return 84.69 | All Time Return 3.5 K |
1 | INVESTOR ALERT Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. on Behalf of Investors | 11/04/2024 |
2 | OncoResponse reports data from Phase I solid tumour treatment trial | 11/08/2024 |
3 | Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria | 11/15/2024 |
4 | Regeneron Pharmaceuticals, Inc. Shares Purchased by GLOBALT Investments LLC GA | 11/19/2024 |
5 | Retireful LLC Buys Shares of 714 Regeneron Pharmaceuticals, Inc. | 11/20/2024 |
6 | BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA through Gamida Cell Ltd. | 11/21/2024 |
7 | Regeneron Pharmaceuticals, Inc.s Price Is Out Of Tune With Earnings | 11/22/2024 |
8 | Earnings call BioLineRx announces Q3 results and strategic shifts | 11/25/2024 |
9 | The Manufacturers Life Insurance Company Sells 2,522 Shares of Regeneron Pharmaceuticals, Inc. | 11/26/2024 |
| Begin Period Cash Flow | 3.1 B |
Regeneron |
Regeneron Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 116,881 in Regeneron Pharmaceuticals on August 31, 2024 and sell it today you would lose (41,394) from holding Regeneron Pharmaceuticals or give up 35.42% of portfolio value over 90 days. Regeneron Pharmaceuticals is currently does not generate positive expected returns and assumes 1.7299% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Regeneron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regeneron Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regeneron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regeneron Pharmaceuticals, and traders can use it to determine the average amount a Regeneron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.391
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | REGN |
Estimated Market Risk
| 1.73 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.68 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.39 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regeneron Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding Regeneron Pharmaceuticals to a well-diversified portfolio.
Regeneron Pharmaceuticals Fundamentals Growth
Regeneron Stock prices reflect investors' perceptions of the future prospects and financial health of Regeneron Pharmaceuticals, and Regeneron Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regeneron Stock performance.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0741 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 75.86 B | ||||
| Shares Outstanding | 108.07 M | ||||
| Price To Earning | 15.51 X | ||||
| Price To Book | 2.83 X | ||||
| Price To Sales | 5.99 X | ||||
| Revenue | 13.12 B | ||||
| Gross Profit | 7.02 B | ||||
| EBITDA | 4.05 B | ||||
| Net Income | 3.95 B | ||||
| Cash And Equivalents | 7.02 B | ||||
| Cash Per Share | 65.75 X | ||||
| Total Debt | 2.7 B | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 272.04 X | ||||
| Cash Flow From Operations | 4.59 B | ||||
| Earnings Per Share | 40.46 X | ||||
| Market Capitalization | 82.95 B | ||||
| Total Asset | 33.08 B | ||||
| Retained Earnings | 27.26 B | ||||
| Working Capital | 16.06 B | ||||
| Current Asset | 2.92 B | ||||
| Current Liabilities | 811.16 M | ||||
About Regeneron Pharmaceuticals Performance
By examining Regeneron Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Regeneron Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Regeneron Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 518.71 | 544.65 | |
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.16 |
Things to note about Regeneron Pharmaceuticals performance evaluation
Checking the ongoing alerts about Regeneron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regeneron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: The Manufacturers Life Insurance Company Sells 2,522 Shares of Regeneron Pharmaceuticals, Inc. |
- Analyzing Regeneron Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regeneron Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Regeneron Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regeneron Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regeneron Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regeneron Pharmaceuticals' stock. These opinions can provide insight into Regeneron Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.46 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.